CC-1088 Celgene.
CC-1088, a thalidomide analog inhibitor of phosphodiesterase 4, was being developed by Celgene for the potential treatment of inflammatory diseases and myelodysplastic syndromes, and had undergone clinical trials. By April 2005, however, the company was no longer developing CC-1088, with CC-10004 presumed to be the preferred compound.
Dredge
Keith
K
Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland 4102, Australia. kdredge@cicr.uq.edu.au
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic; D000075202:Contraindications; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D004345:Drug Industry / Q000458:organization & administration; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D028761:Withholding Treatment
D010726:Phosphodiesterase Inhibitors; D013792:Thalidomide; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; C505730:apremilast